Английская Википедия:Catabasis Pharmaceuticals
Шаблон:Multiple issues Шаблон:Infobox company
Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company.[1] Their lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy.
In Catabasis’s Phase 2 MoveDMD clinical trial and open-label extension, edasalonexent was shown to preserve muscle function as assessed by the North Star Ambulatory Assessment and Timed Function Tests compared with the rate of change during an off-treatment control period. It also showed a significant decrease in CRP, muscle enzymes including CK, and decrease in heart rate to age-normative values.
References
- Английская Википедия
- Biopharmaceutical companies
- Companies listed on the Nasdaq
- Pharmaceutical companies established in 2008
- Health care companies based in Massachusetts
- Companies based in Cambridge, Massachusetts
- Страницы, где используется шаблон "Навигационная таблица/Телепорт"
- Страницы с телепортом
- Википедия
- Статья из Википедии
- Статья из Английской Википедии
